NovoCure Resultados de beneficios anteriores

Pasado controles de criterios 0/6

Los beneficios de NovoCure han disminuido a una tasa media anual de -49.9%, mientras que en la industria Medical Equipment los beneficios crecieron en un 13.5% anualmente. Los ingresos han ido creciendo a una tasa media de 12.2% al año.

Información clave

-55.7%

Tasa de crecimiento de los beneficios

-53.8%

Tasa de crecimiento del BPA

Crecimiento de la industria Medical Equipment	8.9%
Tasa de crecimiento de los ingresos	10.1%
Rentabilidad financiera	-53.6%
Margen neto	-36.7%
Última actualización de beneficios	31 Mar 2024

Actualizaciones de resultados anteriores recientes

Recent updates

Some Shareholders Feeling Restless Over NovoCure Limited's (NASDAQ:NVCR) P/S Ratio

Mar 03

NovoCure: Stay Cautious Amid Positive Signs

Jan 19

Does NovoCure (NASDAQ:NVCR) Have A Healthy Balance Sheet?

Nov 16

Is NovoCure (NASDAQ:NVCR) Weighed On By Its Debt Load?

Aug 13

Is NovoCure (NASDAQ:NVCR) A Risky Investment?

May 15

A Look At The Intrinsic Value Of NovoCure Limited (NASDAQ:NVCR)

Apr 24

Why NovoCure Limited (NASDAQ:NVCR) Could Be Worth Watching

Feb 10

Does NovoCure (NASDAQ:NVCR) Have A Healthy Balance Sheet?

Jan 16

NovoCure: See Past Market Myopia And Buy The Dip

Sep 27

Novocure creates new CNS focused franchise to renew growth in brain cancer business

Sep 21

Does NovoCure (NASDAQ:NVCR) Have A Healthy Balance Sheet?

Sep 09

NovoCure: Does The Reward Outweigh The Risk? I Believe So

Sep 09

NovoCure Q2 2022 Earnings Preview

Jul 27

Is NovoCure (NASDAQ:NVCR) Using Too Much Debt?

May 28

NovoCure: A Stalwart With More Upsides

May 09

Desglose de ingresos y gastos
Beta

Cómo gana y gasta dinero NovoCure. Basado en los últimos beneficios reportados, en base a los últimos doce meses (LTM).

Historial de beneficios e ingresos

NasdaqGS:NVCR Ingresos, gastos y beneficios (USD Millions)
Fecha	Ingresos	Beneficios	Gastos G+A	Gastos de I+D
31 Mar 24	526	-193	387	213
31 Dec 23	509	-207	387	221
30 Sep 23	504	-197	380	224
30 Jun 23	508	-174	354	222
31 Mar 23	522	-141	331	224
31 Dec 22	538	-93	306	206
30 Sep 22	543	-82	289	208
30 Jun 22	545	-68	279	204
31 Mar 22	538	-59	269	198
31 Dec 21	535	-58	263	201
30 Sep 21	546	-27	253	188
30 Jun 21	545	-5	246	173
31 Mar 21	527	12	232	153
31 Dec 20	494	20	225	132
30 Sep 20	450	19	216	112
30 Jun 20	409	12	206	98
31 Mar 20	380	9	197	87
31 Dec 19	351	-7	185	79
30 Sep 19	322	-27	174	70
30 Jun 19	294	-41	166	65
31 Mar 19	269	-55	158	57
31 Dec 18	248	-64	151	51
30 Sep 18	232	-59	143	46
30 Jun 18	217	-59	137	42
31 Mar 18	194	-64	131	40
31 Dec 17	177	-62	123	38
30 Sep 17	154	-73	115	37
30 Jun 17	125	-95	112	37
31 Mar 17	105	-114	108	39
31 Dec 16	83	-132	107	41
30 Sep 16	65	-143	108	44
30 Jun 16	52	-135	96	44
31 Mar 16	41	-124	85	45
31 Dec 15	33	-112	73	44
30 Sep 15	25	-102	60	44
30 Jun 15	20	-94	53	43
31 Mar 15	18	-86	49	41
31 Dec 14	15	-81	45	40
31 Dec 13	10	-77	33	35

Ingresos de calidad: NVCR actualmente no es rentable.

Margen de beneficios creciente: NVCR actualmente no es rentable.

Análisis del flujo de caja libre vs. Beneficios

Análisis del crecimiento de los beneficios en el pasado

Tendencia de beneficios: NVCR no es rentable, y las pérdidas han aumentado en los últimos 5 años a un ritmo de 49.9% al año.

Acelerando crecimiento: No se puede comparar el crecimiento de los beneficios de NVCR en el último año con su promedio de 5 años, ya que actualmente no es rentable.

Beneficios vs. Industria: NVCR no es rentable, por lo que resulta difícil comparar el crecimiento de sus beneficios en el último año con el de la industria Medical Equipment (3.3%).

Rentabilidad financiera

Alta ROE: NVCR tiene una rentabilidad financiera negativa (-57.12%), ya que actualmente no es rentable.

NovoCure Resultados de beneficios anteriores

Pasado controles de criterios 0/6

Información clave

Actualizaciones de resultados anteriores recientes

First quarter 2024 earnings: EPS and revenues exceed analyst expectations

NovoCure Limited to Report Q1, 2024 Results on May 02, 2024

Full year 2023 earnings: EPS exceeds analyst expectations

Third quarter 2023 earnings released: US$0.46 loss per share (vs US$0.25 loss in 3Q 2022)

NovoCure Limited to Report Q3, 2023 Results on Oct 26, 2023

Second quarter 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

Recent updates

NovoCure Limited announced that it expects to receive $400 million in funding

NovoCure Limited Q1 Earnings: Core Business Accelerating

NovoCure Limited announced that it expects to receive $400 million in funding

First quarter 2024 earnings: EPS and revenues exceed analyst expectations

NovoCure Limited Announces Results of the Metis Phase 3 Clinical Trial in Brain Metastases from Non-Small Cell Lung Cancer

NovoCure Limited, Annual General Meeting, Jun 05, 2024

New minor risk - Insider selling

New minor risk - Shareholder dilution

NovoCure (NASDAQ:NVCR) Has Debt But No Earnings; Should You Worry?

NovoCure Limited to Report Q1, 2024 Results on May 02, 2024

NovoCure: Sell The METIS-Inspired Rally

Price target increased by 8.8% to US$27.20

Some Shareholders Feeling Restless Over NovoCure Limited's (NASDAQ:NVCR) P/S Ratio

Full year 2023 earnings: EPS exceeds analyst expectations

NovoCure: Stay Cautious Amid Positive Signs

Novocure Announces FDA Acceptance of the PMA Application for TTFields Therapy in Non-Small Cell Lung Cancer

NovoCure Limited Announces Last Patient Enrolled in Phase 3 Trident Trial in Newly Diagnosed Glioblastoma

NovoCure Limited Announces Executive Changes

Novocure Announces Portfolio Prioritization and Strategic Restructuring Plan Focused on Near-Term Growth Drivers and an Accelerated Path to Profitability

Does NovoCure (NASDAQ:NVCR) Have A Healthy Balance Sheet?

Chief Financial Officer exercised options to buy US$231k worth of stock.

Third quarter 2023 earnings released: US$0.46 loss per share (vs US$0.25 loss in 3Q 2022)

NovoCure Limited to Report Q3, 2023 Results on Oct 26, 2023

NovoCure Limited(NasdaqGS:NVCR) dropped from FTSE All-World Index (USD)

Novocure Announces the Lancet Oncology Publishes Primary Data from Phase 3 Lunar Clinical Trial in Patients with Metastatic Non-Small Cell Lung Cancer After Platinum-Based Therapies

Price target decreased by 42% to US$35.17

Is NovoCure (NASDAQ:NVCR) Weighed On By Its Debt Load?

Price target decreased by 9.4% to US$60.33

Levi & Korsinsky Notifies NovoCure Limited Investors of a Class Action Lawsuit and Upcoming Deadline

New major risk - Revenue and earnings growth

Second quarter 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

Novocure Announces Favorable Independent Data Monitoring Committee Recommendation to Continue Phase 3 Panova-3 Clinical Trial of Tumor Treating Fields Therapy in Pancreatic Cancer

NovoCure Limited to Report Q2, 2023 Results on Jul 27, 2023

Holzer & Holzer, LLC Files Lawsuit Against NovoCure Limited

Price target decreased by 16% to US$64.17

Zai Lab and Novocure Announces Lunar Phase 3 Clinical Trial Demonstrates Statistically Significant and Clinically Meaningful Extension in Overall Survival for Patients with Metastatic Non-Small Cell Lung Cancer After Platinum-Based Therapies

Is NovoCure (NASDAQ:NVCR) A Risky Investment?

Consensus EPS estimates fall by 31%

First quarter 2023 earnings: EPS and revenues miss analyst expectations

Price target decreased by 20% to US$82.00

A Look At The Intrinsic Value Of NovoCure Limited (NASDAQ:NVCR)

Consensus EPS estimates fall by 12%

Chief Operating Officer notifies of intention to sell stock

Chief Operating Officer recently sold US$165k worth of stock

Consensus EPS estimates fall by 31%

Full year 2022 earnings released: US$0.88 loss per share (vs US$0.56 loss in FY 2021)

Novocure Announces Last Patient Enrolled in Pivotal PANOVA-3 Study of Tumor Treating Fields in Pancreatic Cancer

Why NovoCure Limited (NASDAQ:NVCR) Could Be Worth Watching

Novocure Announces Executive Changes

Does NovoCure (NASDAQ:NVCR) Have A Healthy Balance Sheet?

President notifies of intention to sell stock

Zai Lab Limited and Novocure Announce Pivotal Lunar Study in Non-Small Cell Lung Cancer Met Primary Overall Survival Endpoint

Price target increased to US$98.86

Insufficient new directors

Third quarter 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

Novocure Announces 11 Presentations on Tumor Treating Fields in Multiple Solid Tumor Types at the American Society for Radiation Oncology 2022 Annual Meeting

Chief Development Officer notifies of intention to sell stock

Chief Development Officer notifies of intention to sell stock

Chief Development Officer notifies of intention to sell stock

NovoCure Limited to Report Q3, 2022 Results on Oct 27, 2022

NovoCure: See Past Market Myopia And Buy The Dip

Chief Development Officer notifies of intention to sell stock

Novocure creates new CNS focused franchise to renew growth in brain cancer business

Chief Development Officer notifies of intention to sell stock

Does NovoCure (NASDAQ:NVCR) Have A Healthy Balance Sheet?

NovoCure: Does The Reward Outweigh The Risk? I Believe So

Chief Financial Officer recently sold US$70k worth of stock

Executive Chairman recently sold US$58k worth of stock

Second quarter 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

Desglose de ingresos y gastos
Beta